Please use this link if your mail program does not display this newsletter correctly. You will be forwarded to our website.


Photo: Evotec Laboratory (Source: Evotec)
With the takeovers of the MPS (Max Planck Society) spin-offs Kinaxo and, previously, Develogen AG, several outstanding technologies developed at various Max Planck institutes (MPI) are now being brought together and further developed under the powerful umbrella of Evotec AG, which also had its start at a Max Planck institute. continue
The researchers of the Max Planck institutes (MPI) have received some very important awards during the past months. The Leibniz price 2011 goes to scientist of the Max Planck Society (MPS). In addition, most Grants of the European Research Council were awarded in Europe as well as in Germany to the MPS. Also the Max-Planck-research price 2011 and the Louis Jeantet price of medicine goes to the researchers of the MPS. continue

Image: VLP project group in front of caesar in Bonn (Source: LSI)
As part of its unique incubation concept, the company Life Science Inkubator (LSI), located at the center of advanced european studies and research (caesar) in Bonn, accommodates spin-off projects from the fields of biotechnology, pharmacology and medical technology at its premises with a view to developing them to the stage when they are ready for financing. LSI, which has been initiated by Max Planck Innovation itself, currently has a lot of new developments and innovations to report. In addition to the fact that two renowned research organisations have come on board as shareholders, LSI now also has the status of a research institution itself. Moreover, another very promising project will shortly be incubated, and the VLP pioneer project is now ready to enter the transfer phase. A newly established cooperation agreement with the company High-Tech Gründerfonds (HTGF) is expected to also bring new projects to LSI. continue

In March 2011 Excelitas Technologies announced breakthrough performance results with its Solid State Silicon Photomultiplier (SiPM) Technology, which it has licensed from Max Planck Innovation. SiPM is well-suited for a host of low light level detection applications in analytical instruments, clinical diagnostics, and life sciences. continue

The German Center for Research & Innovation (GCRI) in New York was opened one year ago by the Federal Minister of Research and Education, Prof. Dr. Annette Schavan, and the German Ambassador to the United States, Dr. Klaus Scharioth. Now the website of the GCRI is online and will provide an information platform for the German research and innovation landscape. continue

More than 1.000 followers on Twitter
Are you interested in current technological products and the latest information from the Max Planck Society’s various research fields? More than 1.000 followers are already receiving our tweets on the microblogging platform under www.twitter.com/mp_innovation.
A highly selective F-actin affinity matrix for comprehensive mappings of F actin interaction networks (11.06.2013)
Small Molecule Inhibitors of Chemotaxis for the Treatment of Acute Inflammatory Diseases (11.06.2013)
Guaranteed self-organized synchronization of distributed sensor networks (11.06.2013)

Photo: Approximately 180 representatives of pharmaceutical, biotech, VC and technology transfer companies are expected to attend the BioVaria 2011 fair
Numerous visitors are expected to attend BioVaria 2011 to inform themselves about “Europe’s Next Top Technologies”, i.e. the latest licensable technologies developed by leading university and non-university research institutions in Europe. Max Planck Innovation is again main partner and co-organiser of the technology fair, which takes place for the third time this year. continue
Your suggestions, wishes or comments are welcome via E-Mail to: redaktion@max-planck-innovation.de
Do you want to receive our newsletter and press releases?
Subscribe here
8th Biotech NetWorkshop at Ringberg Castle
Cenix BioScience and Debiopharm GroupTM collaborate to identify predictive biomarkers. More
Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis (ATTR). More
Chinese diagnostics company BioChain has licensed Epigenomics’ methylated Septin9 marker for the blood based detection of colorectal cancer. More
Markus Berninger
Phone: (089) 290919-30